The report forecasts the global CLL therapeutics market to grow at a CAGR of 19.16% during the period 2016-2020.
- What will the market size be in 2020 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Commenting on the report, an analyst from the research team said: A trend that is expected to boost market growth is a rise in the development of combination therapies. Combination therapies for the treatment of CLL were available only in the form of chemotherapy combination drugs. The approved combinations are chlorambucil in combination with prednisone, and a combination of cyclophosphamide with vincristine and prednisone. However, a growing trend of developing combination therapies to treat CLL has been observed. For instance, TG Therapeutics develops TG-1101 in combination with ibrutinib to treat CLL and MCL. Similarly, the company also develops TG-1101 in combination with TGR-1202 to treat CLL and NHL.
According to the report, a key growth driver is the special regulatory designations offered to certain drugs. Diseases that affect a small percentage of the population, such as CLL, are treated by a few marketed drugs. A small number of patients implies that there is a small market for these0 drugs, so it may not be profitable for companies to develop these drugs as recovering the R&D expenses would be difficult. To compensate for this limitation and encourage the development of such drugs, regions such as the US and the EU award an Orphan Drug Designation or Breakthrough Therapy Designation to certain drugs.
- F. Hoffman-La Roche
- Teva Pharmaceuticals
- Gilead Sciences
- Johnson & Johnson
- Altor BioScience
- Arno Therapeutics
- Bellicum Pharmaceuticals
- Boston Biomedical
- Emergent BioSolutions
PART 01: Executive summary
PART 02: Scope of the report
PART 03: Market research methodology
PART 04: Introduction
PART 05: Disease overview
PART 06: Pipeline analysis
PART 07: Market landscape
PART 08: Market segmentation by ROA
PART 09: Market segmentation by type of molecule
PART 10: Geographical segmentation
PART 11: Market drivers
PART 12: Impact of drivers
PART 13: Market challenges
PART 14: Impact of drivers and challenges
PART 15: Market trends
PART 16: Vendor landscape
PART 17: Appendix
PART 18: About the Author
For more information visit http://www.researchandmarkets.com/research/fqlh94/global_chronic
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/research-and-markets---global-chronic-lymphocytic-leukemia-market-cagr-growth-of-1916-by-2020---analysis-technologies--forecasts-report-2016-2020---key-vendors-abbvie-amgen-novartis-300293827.html
SOURCE Research and Markets